Health
Vaccination in patients with kidney failure: lessons from COVID-19
Kooman, J. P., Kotanko, P., Schols, A. M. W. J., Shiels, P. G. & Stenvinkel, P. Chronic kidney disease and premature ageing. Nat. Rev. Nephrol. 10, 732–742 (2014).
Crépin, T. et al. Uraemia-induced immune senescence and clinical outcomes in chronic kidney disease patients. Nephrol. Dial. Transpl. 35, 624–632 (2020).
Kotton, C. N. Immunization after kidney transplantation — what is necessary and what is safe? Nat. Rev. Nephrol. 10, 555–562 (2014).
Lynn, D. J., Benson, S. C., Lynn, M. A. & Pulendran, B. Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-021-00554-7 (2021).
Zimmermann, P. & Curtis, N. Factors that influence the immune response to vaccination. Clin. Microbiol. Rev. 32, e00084-18 (2019).
Ma, B. M. et al. Vaccination in patients with chronic kidney disease — review of current recommendations and recent advances. Nephrology 26, 5–11 (2021).
Kato, S. et al. Aspects of immune dysfunction in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 3, 1526–1533 (2008).
Krueger, K. M., Ison, M. G. & Ghossein, C. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am. J. Kidney Dis. 75, 417–425 (2020).
Uribarri, A. et al. Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry. J. Nephrol. 19, 1–9 (2020).
Kant, S. et al. The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation. BMC Nephrol. 21, 1–13 (2020).
Anft, M. et al. COVID-19-induced ARDS is associated with decreased frequency of activated memory/effector T cells expressing CD11a++. Mol. Ther. 28, 2691–2702 (2020).
Thieme, C. J. et al. Robust T cell response toward spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients. Cell Rep. Med. 1, 100092 (2020).
Hartzell, S. et al. Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. Am. J. Transplant. 20, 3149–3161 (2020).
Candon, S. et al. T cell and antibody responses to SARS-CoV-2: experience from a French transplantation and hemodialysis center during the COVID-19 pandemic. Am. J. Transplant. 21, 854–863 (2021).
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83–100 (2021).
Quinti, I. et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J. Allergy Clin. Immunol. 146, 211 (2020).
Soresina, A. et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr. Allergy Immunol. 31, 565–569 (2020).
Vanholder, R. et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 63, 1934–1943 (2003).
Cohen, G., Raupachova, J. & Hörl, W. H. The uraemic toxin phenylacetic acid contributes to inflammation by priming polymorphonuclear leucocytes. Nephrol. Dial. Transpl. 28, 421–429 (2013).
Yu, M., Kim, Y. J. & Kang, D. H. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin. J. Am. Soc. Nephrol. 6, 30–39 (2011).
Kim, H. Y. et al. Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD). Sci. Rep. 7, 3057 (2017).
Azevedo, M. L. V. et al. p-Cresyl sulfate affects the oxidative burst, phagocytosis process, and antigen presentation of monocyte-derived macrophages. Toxicol. Lett. 263, 1–5 (2016).
Daenen, K. et al. Oxidative stress in chronic kidney disease. Pediatr. Nephrol. 34, 975–991 (2019).
Duni, A., Liakopoulos, V., Roumeliotis, S., Peschos, D. & Dounousi, E. Oxidative stress in the pathogenesis and evolution of chronic kidney disease: untangling Ariadne’s thread. Int. J. Mol. Sci. 20, 3711 (2019).
Sanlioglu, S. et al. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-α secretion through IKK regulation of NF-κB. J. Biol. Chem. 276, 30188–30198 (2001).
Steiger, S., Rossaint, J., Zarbock, A. & Anders, H. J. Secondary immunodeficiency related to kidney disease (SIDKD) — definition, unmet need, and mechanisms. J. Am. Soc. Nephrol. 33, 259–278 (2022).
Anders, H. J., Andersen, K. & Stecher, B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int. 83, 1010–1016 (2013).
Lang, C.-L., Wang, M.-H., Chiang, C.-K. & Lu, K.-C. Vitamin D and the immune system from the nephrologist’s viewpoint. ISRN Endocrinol. 2014, 105456 (2014).
Adorini, L. & Penna, G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum. Immunol. 70, 345–352 (2009).
Lemire, J. M., Archer, D. C., Beck, L. & Spiegelberg, H. L. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J. Nutr. 125, 1704S–1708S (1995).
Boonstra, A. et al. 1α,25-Dihydroxyvitamin D3 has a direct effect on naive CD4+ T cells to enhance the development of Th2 cells. J. Immunol. 167, 4974–4980 (2001).
Jeffery, L. E. et al. 1,25-Dihydroxyvitamin D 3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol. 183, 5458–5467 (2009).
Massry, S. G. & Smogorzewski, M. Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone. Kidney Int. 59, 195–196 (2001).
Cantarelli, C., Angeletti, A. & Cravedi, P. Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. Am. J. Transplant. 19, 2407–2414 (2019).
Libetta, C., Sepe, V. & Canton, A. D. Bio-incompatibility and Th2 polarization during regular dialysis treatment. Int. Rev. Immunol. 29, 608–625 (2010).
Zanoni, I. et al. CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature 460, 264–268 (2009).
Carracedo, J. et al. Cell apoptosis and hemodialysis-induced inflammation. Kidney Int. Suppl. 61, 89–93 (2002).
Fukushi, T., Yamamoto, T., Yoshida, M., Fujikura, E. & Miyazaki, M. Enhanced neutrophil apoptosis accompanying myeloperoxidase release during hemodialysis. Sci. Rep. 10, 21747 (2020).
Kourtzelis, I. et al. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 116, 631–639 (2010).
Xiang, F. et al. Decreased peripheral naïve T cell number and its role in predicting cardiovascular and infection events in hemodialysis patients. Front. Immunol. 12, 1–9 (2021).
Naylor, K. et al. The influence of age on T cell generation and TCR diversity. J. Immunol. 174, 7446–7452 (2005).
Litjens, N. H. R., Van Druningen, C. J. & Betjes, M. G. H. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin. Immunol. 118, 83–91 (2006).
Betjes, M. G. H., Langerak, A. W., Van Der Spek, A., De Wit, E. A. & Litjens, N. H. R. Premature aging of circulating T cells in patients with end-stage renal disease. Kidney Int. 80, 208–217 (2011).
Betjes, M. G. H. Uremia-associated ageing of the thymus and adaptive immune responses. Toxins 12, 224 (2020).
Ebert, T. et al. Inflammation and premature ageing in chronic kidney disease. Toxins 12, 227 (2020).
Cohen, G. Immune Dysfunction in Uremia 2020. Toxins 12, 439 (2020).
Meier, P., Dayer, E. & Blanc, E. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease.13, 204–212 (2002).
Stavropoulou, E. et al. Microbiome, immunosenescence, and chronic kidney disease. Front. Med. 8, 1–8 (2021).
Akchurin, O. M. & Kaskel, F. Update on inflammation in chronic kidney disease. Blood Purif. 39, 84–92 (2015).
Mathew, R., Mason, D. & Kennedy, J. S. Vaccination issues in patients with chronic kidney disease. Expert. Rev. Vaccines 13, 285–298 (2014).
Ishigami, J. & Matsushita, K. Clinical epidemiology of infectious disease among patients with chronic kidney disease. Clin. Exp. Nephrol. 23, 437–447 (2019).
Dalrymple, L. S. & Go, A. S. Epidemiology of acute infections among patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 3, 1487–1493 (2008).
Lai, C. C. et al. COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert. Rev. Vaccines 20, 1013–1025 (2021).
Cevik, M., Grubaugh, N. D., Iwasaki, A. & Openshaw, P. COVID-19 vaccines: keeping pace with SARS-CoV-2 variants. Cell 184, 5077–5081 (2021).
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020).
Nance, K. D. & Meier, J. L. Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines. ACS Cent. Sci. 7, 748–756 (2021).
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501.e15 (2020).
Lu, S. et al. The immunodominant and neutralization linear epitopes for SARS-CoV-2. Cell Rep. 34, 108666 (2021).
Swadling, L. et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature https://doi.org/10.1038/s41586-021-04186-8 (2021).
Rincon-Arevalo, H. et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci. Immunol. 6, 1–13 (2021).
Leyendeckers, H. et al. Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Eur. J. Immunol. 29, 1406–1417 (1999).
Odendahl, M. et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105, 1614–1621 (2005).
Tan, H. Z. et al. Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int. 100, 467–471 (2021).
Furer, V. et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann. Rheum. Dis. 80, 1330–1338 (2021).
Boyarsky, B. J. et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 325, 2204–2206 (2021).
Stumpf, J. et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg. Health Eur. https://doi.org/10.1016/j.lanepe.2021.100178 (2021).
Sattler, A. et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J. Clin. Invest 131, e150175 (2021).
Thieme, C. J. et al. The magnitude and functionality of SARS-CoV-2 reactive cellular and humoral immunity in transplant population is similar to the general population despite immunosuppression. Transplantation 105, 2156–2164 (2021).
Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032–2040 (2021).
Chen, J. J. et al. Immunogenicity rates after SARS-CoV-2 vaccination in people with end-stage kidney disease: a systematic review and meta-analysis. JAMA Netw. Open 4, e2131749 (2021).
Broseta, J. et al. Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients. Am. J. Kidney Dis. 78, 571–581 (2021).
Midtvedt, K. et al. Low immunization rate in kidney transplant recipients also after dose 2 of the BNT162b2 vaccine: continue to keep your guard up! Transplantation 105, E80–E81 (2021).
Cucchiari, D. et al. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am. J. Transplant. 21, 2727–2739 (2021).
Hackstein, H. & Thomson, A. W. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. 4, 24–34 (2004).
Taylor, A. L., Watson, C. J. E. & Bradley, J. A. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit. Rev. Oncol. Hematol. 56, 23–46 (2005).
Allison, A. C. Mechanisms of action of mycophenolate mofetil. Lupus 14, 2–8 (2005).
Haneda, M. et al. Comparative analysis of drug action on B-cell proliferation and differentiation for mycophenolic acid, everolimus, and prednisolone. Transplantation 97, 405–412 (2014).
Karnell, J. L. et al. Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. J. Immunol. 187, 3603–3612 (2011).
Rozen-Zvi, B. et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin. Microbiol. Infect. J. 27, 1173.e1–1173.e4 (2021).
Broen, J. C. A. & van Laar, J. M. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat. Rev. Rheumatol. 16, 167–178 (2020).
Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12, 325–338 (2012).
Mannick, J. B. et al. mTOR inhibition improves immune function in the elderly. Sci. Transl. Med. 6, 268ra179 (2014).
Lages, C. S., Lewkowich, I., Sproles, A., Wills-Karp, M. & Chougnet, C. Partial restoration of T cell function in aged mice by in vitro blockade of the PD-1/PD-L1 pathway. Aging Cell 9, 785–798 (2010).
Gardner, D., Jeffery, L. E. & Sansom, D. M. Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. Am. J. Transpl. 14, 1985–1991 (2014).
Chavarot, N. et al. Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept. Transplantation 105, E94–E95 (2021).
Bertrand, D. et al. Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients. J. Am. Soc. Nephrol. 32, 2147–2152 (2021).
Ou, M. T. et al. Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking belatacept. Transplantation 105, 2119–2123 (2021).
Terrec, F. et al. Belatacept use after kidney transplantation and its effects on risk of infection and COVID-19 vaccine response. J. Clin. Med. 10, 5159 (2021).
Leibler, C. et al. Control of humoral response in renal transplantation by belatacept depends on a direct effect on B cells and impaired T follicular helper-B cell crosstalk. J. Am. Soc. Nephrol. 29, 1049–1062 (2018).
Chen, J. et al. Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig. Am. J. Transpl. 13, 2280–2292 (2013).
Bertrand, D. et al. Opportunistic infections after conversion to belatacept in kidney transplantation. Nephrol. Dial. Transpl. 35, 336–345 (2020).
Scharpé, J. et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am. J. Transpl. 8, 332–337 (2008).
Rambal, V. et al. Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients. Med. Microbiol. Immunol. 203, 35–45 (2014).
Birdwell, K. A. et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am. J. Kidney Dis. 54, 112–121 (2009).
Morillo-Huesca, M., Vanti, M. & Chávez, S. A simple in vivo assay for measuring the efficiency of gene length-dependent processes in yeast mRNA biogenesis. FEBS J. 273, 756–769 (2006).
Jurkiewicz, A. et al. Inhibition of tRNA gene transcription by the immunosuppressant mycophenolic acid. Mol. Cell. Biol. 40, e00294-19 (2019).
Dieci, G., Fiorino, G., Castelnuovo, M., Teichmann, M. & Pagano, A. The expanding RNA polymerase III transcriptome. Trends Genet. 23, 614–622 (2007).
Graczyk, D., Cieśla, M. & Boguta, M. Regulation of tRNA synthesis by the general transcription factors of RNA polymerase III, TFIIIB and TFIIIC, and by the MAF1 protein. Biochim. Biophys. Acta Gene Regul. Mech. 1861, 320–329 (2018).
Orioli, A., Praz, V., Lhôte, P. & Hernandez, N. Human MAF1 targets and represses active RNA polymerase III genes by preventing recruitment rather than inducing long-term transcriptional arrest. Genome Res. 26, 624–634 (2016).
Sans, M. D. & Williams, J. A. Calcineurin is required for translational control of protein synthesis in rat pancreatic acini. Am. J. Physiol. Cell Physiol. 287, C310–C319 (2004).
Benotmane, I. et al. In-depth virological assessment of kidney transplant recipients with COVID-19. Am. J. Transplant. 20, 3162–3172 (2020).
Favà, A. et al. SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients. Am. J. Transplant. 21, 2749–2761 (2021).
Wijtvliet, V. P. W. M. et al. mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients? Nephrol. Dial. Transpl. 37, 799–803 (2022).
Van Praet, J. et al. Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 mRNA vaccines in hemodialysis patients: a multicenter observational study. J. Am. Soc. Nephrol. 32, 3208–3220 (2021).
Benotmane, I. et al. Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19. Am. J. Transplant. 21, 3808–3810 (2021).
Grupper, A. et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am. J. Transplant. 21, 2719–2726 (2021).
Mehta, R. B. & Silveira, F. P. COVID-19 after two doses of mRNA vaccines in kidney transplant recipients. Am. J. Transplant. https://doi.org/10.1111/ajt.16778 (2021).
Chavarot, N. et al. Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept. Am. J. Transplant. https://doi.org/10.1111/ajt.16814 (2021).
Caillard, S. et al. Occurrence of severe COVID-19 in vaccinated transplant patients. Kidney Int. 100, 457–481 (2021).
Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 1–10 (2022).
Chen, J., Wang, R., Gilby, N. B. & Wei, G.-W. Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J. Chem. Inf. Model. https://doi.org/10.1021/acs.jcim.1c01451 (2022).
Chen, Y. et al. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerg. Microbes Infect. 6, 1–7 (2017).
Wang, L. et al. Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the middle east respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape. J. Virol. 92, 1–21 (2018).
Wall, E. C. et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 397, 2331–2333 (2021).
Speer, C. et al. Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2. Kidney Int. 100, 700–702 (2021).
Manley, H. J. et al. SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients. Preprint at medRxiv https://doi.org/10.1101/2021.12.20.21268124 (2021).
Thieme, C. J. et al. Impaired humoral but substantial cellular immune response to variants of concern b1.1.7 and b.1.351 in hemodialysis patients. J. Am. Soc. Nephrol. 32, 2725–2727 (2021).
Kumar, D. et al. Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. Am. J. Transplant. https://doi.org/10.1111/ajt.17020 (2022).
Stervbo, U. et al. Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease. Kidney Int. https://doi.org/10.1016/j.kint.2021.09.015 (2021).
Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847–859.e11 (2022).
Gao, Y. et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med. 28, 472–476 (2022).
Davidovic, T. et al. Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost. Kidney Int. https://doi.org/10.1016/j.kint.2021.10.006 (2021).
Aslam, S., Adler, E., Mekeel, K. & Little, S. J. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transpl. Infect. Dis. 23, 19–21 (2021).
Qin, C. X. et al. Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients. Transplantation 105, e265–e266 (2021).
Bertrand, D. et al. Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients. Am. J. Transplant. https://doi.org/10.1111/ajt.16954 (2022).
ECDC and EMA. Updated joint statement from ECDC and EMA on additional booster doses of COVID-19 vaccines. EMA/635144, (2022).
Benotmane, I. et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. J. Am. Med. Assoc. 326, 1063–1065 (2021).
Bertrand, D. et al. Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients. Kidney Int. https://doi.org/10.1016/j.kint.2021.09.014 (2021).
Charmetant, X. et al. Predictive factors of a viral neutralizing humoral response after a third dose of COVID-19 mRNA vaccine. Am. J. Transplant. https://doi.org/10.1111/ajt.16990 (2022).
Hall, V. G. et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N. Engl. J. Med. 385, 1244–1246 (2021).
Kamar, N. et al. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. N. Engl. J. Med. 385, 661–662 (2021).
Marlet, J. et al. Antibody responses after a third dose of COVID-19 vaccine in kidney transplant recipients and patients treated for chronic lymphocytic leukemia. Vaccines 9, 4–9 (2021).
Massa, F. et al. Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients. EBioMedicine 73, 103679 (2021).
Masset, C. et al. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response. Kidney Int. 100, 1132–1135 (2021).
Schrezenmeier, E. et al. B and T cell responses after a third dose of SARS-CoV-2 vaccine in kidney transplant recipients. J. Am. Soc. Nephrol. https://doi.org/10.1681/asn.2021070966 (2021).
Stumpf, J. et al. Cellular and humoral immune responses after three doses of BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant. Transplantation 105, 267–269 (2021).
Westhoff, T. H. et al. A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse. Kidney Int. 100, 1135–1136 (2021).
Espi, M. et al. A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. Kidney Int. 101, 390–402 (2022).
Alejo, J. L. et al. Antibody response to a fourth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Transplantation 105, E280–E281 (2021).
Benotmane, I. et al. A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients. Kidney Int. 50, 5–8 (2022).
Caillard, S., Thaunat, O., Benotmane, I., Masset, C. & Blancho, G. Antibody response to a fourth messenger RNA COVID-19 vaccine dose in kidney transplant recipients: a case series. Ann. Intern. Med. 175, 455–456 (2022).
Cinkilic, O. et al. Inferior humoral and sustained cellular immunity against wild-type and omicron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses. Kidney Int. https://doi.org/10.1016/j.kint.2022.03.005 (2022).
Kamar, N. et al. Assessment of 4 doses of SARS-CoV-2 messenger RNA-based vaccine in recipients of a solid organ transplant. JAMA Netw. Open 4, e2136030 (2021).
Masset, C. et al. A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients. Kidney Int. 101, 825–826 (2022).
Osmanodja, B. et al. Serological response to three, four and five doses of SARS-CoV-2 vaccine in kidney transplant recipients. J. Clin. Med. 11, 2565 (2022).
Roch, T. et al. A vector-based vaccine dose after 3 doses of mRNA-based COVID-19 vaccination does not substantially improve humoral SARS-CoV-2 immunity in renal transplant recipients. Kidney Int. Rep. 7, 932–934 (2022).
Schrezenmeier, E. et al. Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. JCI Insight 7, e157836 (2022).
Karaba, A. H. et al. A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients. Am. J. Transplant. 22, 1253–1260 (2022).
Del Bello, A. et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am. J. Transplant. https://doi.org/10.1111/ajt.16775 (2021).
Del Bello, A. et al. Acute rejection after anti-SARS-CoV-2 mRNA vaccination in a patient who underwent a kidney transplant. Kidney Int. 100, 238–239 (2021).
Werbel, W. A. et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann. Intern. Med. 174, 1330–1332 (2021).
Duchini, A., Goss, J. A., Karpen, S. & Pockros, P. J. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin. Microbiol. Rev. 16, 357–364 (2003).
Danziger-Isakov, L. & Kumar, D. Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation Infectious Diseases community of practice. Clin. Transplant. 33, 1–10 (2019).
Chong, P. P., Handler, L. & Weber, D. J. A systematic review of safety and immunogenicity of influenza vaccination strategies in solid organ transplant recipients. Clin. Infect. Dis. 66, 1802–1811 (2018).
Cordero, E. et al. Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: results of TRANSGRIPE 1-2, a randomized controlled clinical trial. Clin. Infect. Dis. 64, 829–838 (2017).
Pascual, J. et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 82, 55–61 (2006).
Lanzavecchia, A. & Sallusto, F. Progressive differentiation and selection of the fittest in the immune response. Nat. Rev. Immunol. 2, 982–987 (2002).
Sullivan, K. M. et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N. Engl. J. Med. 323, 1120–1123 (1990).
Irvine, D. J., Swartz, M. A. & Szeto, G. L. Engineering synthetic vaccines using cues from natural immunity. Nat. Mater. 12, 978–990 (2013).
Miskulin, D. C. et al. High-dose seasonal influenza vaccine in patients undergoing dialysis. Clin. J. Am. Soc. Nephrol. 13, 1693–1702 (2018).
Haddadin, Z. et al. Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients. Am. J. Transplant. 21, 938–949 (2021).
Kosmadakis, G., Albaret, J., Correia, E. D. C., Somda, F. & Aguilera, D. Vaccination practices in dialysis patients: a narrative review. Semin. Dial. 31, 507–518 (2018).
Babu, T. M. & Kotton, C. N. Immunizations in chronic kidney disease and kidney transplantation. Curr. Treat. Options Infect. Dis. 13, 47–65 (2021).
Noh, J. Y. et al. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines. Hum. Vaccines Immunother. 12, 2902–2908 (2016).
Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532–542 (2022).
Morais, P., Adachi, H. & Yu, Y. T. The critical contribution of pseudouridine to mRNA COVID-19 vaccines. Front. Cell Dev. Biol. 9, 1–9 (2021).
Barraclough, K. A. et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am. J. Kidney Dis. 54, 95–103 (2009).
Yousaf, F., Gandham, S., Galler, M., Spinowitz, B. & Charytan, C. Systematic review of the efficacy and safety of intradermal versus intramuscular hepatitis B vaccination in end-stage renal disease population unresponsive to primary vaccination series. Ren. Fail. 37, 1080–1088 (2015).
Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).
Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664–670 (2022).
Wilhelm, A. et al. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. EBioMedicine 82, 104158 (2022).
Paniskaki, K. et al. Immune response in moderate to critical breakthrough COVID-19 infection after mRNA vaccination. Front. Immunol. 13, 1–11 (2022).
Bensouna, I. et al. SARS-CoV-2 antibody response after a third dose of the BNT162b2 vaccine in patients receiving maintenance hemodialysis or peritoneal dialysis. Am. J. Kidney Dis. https://doi.org/10.1053/j.ajkd.2021.08.005 (2021).
Dekervel, M. et al. Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis. Clin. Kidney J. https://doi.org/10.1093/ckj/sfab152 (2021).
Ducloux, D., Colladant, M., Chabannes, M., Yannaraki, M. & Courivaud, C. Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. Kidney Int. 100, 702–704 (2021).
Longlune, N. et al. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol. Dial. Transpl. 36, 1704–1709 (2021).
Robert, T. et al. Humoral response after SARS-COV2 vaccination in patient undergoing maintenance hemodialysis: loss of immunity, third dose and non-responders. Nephrol. Dial. Transpl. https://doi.org/10.1093/ndt/gfab299 (2021).
Anand, S. et al. Antibody response to COVID-19 vaccination in patients receiving dialysis. J. Am. Soc. Nephrol. 32, 2435–2438 (2021).
Bassi, J. et al. Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. PLoS One 17, e0263328 (2022).
Billany, R. E. et al. Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms. Kidney Int. 99, 1492–1494 (2021).
Brunelli, A. S. M. et al. Comparative effectiveness of BNT162b2 versus Ad26.COV2.S for the prevention of COVID-19 among dialysis patients. Preprint at medRxiv https://doi.org/10.1101/2021.10.21.21265339 (2021).
Dębska-Ślizień, A. et al. Predictors of humoral response to mRNA COVID19 vaccines in kidney transplant recipients: a longitudinal study — the COViNEPH project. Vaccines 9, 1165 (2021).
Garcia, P. et al. COVID19 vaccine type and humoral immune response in patients receiving dialysis. J. Am. Soc. Nephrol. https://doi.org/10.1681/asn.2021070936 (2021).
Hsu, C. M. et al. Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients. Am. J. Kidney Dis. https://doi.org/10.1053/j.ajkd.2021.10.002 (2021).
Husain, S. A. et al. Postvaccine anti-SARS-CoV-2 spike protein antibody development in kidney transplant recipients. Kidney Int. Rep. 6, 1699–1700 (2021).
Kaiser, R. A., Haller, M. C., Apfalter, P., Kerschner, H. & Cejka, D. Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients. Kidney Int. 100, 697–698 (2021).
Lacson, E. et al. Immunogenicity of SARS-CoV-2 vaccine in dialysis. J. Am. Soc. Nephrol. 32, 2735–2742 (2021).
Mulhern, J. G. et al. Humoral response to mRNA versus an adenovirus vector-based SARS-CoV-2 vaccine in dialysis patients. Clin. J. Am. Soc. Nephrol. https://doi.org/10.2215/cjn.06450521 (2021).
Prendecki, M. et al. Comparison of humoral and cellular responses in kidney transplant recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines. Preprint at medRxiv https://doi.org/10.1101/2021.07.09.21260192 (2021).
|
Sources 2/ https://www.nature.com/articles/s41581-022-00617-5 The mention sources can contact us to remove/changing this article |
What Are The Main Benefits Of Comparing Car Insurance Quotes Online
LOS ANGELES, CA / ACCESSWIRE / June 24, 2020, / Compare-autoinsurance.Org has launched a new blog post that presents the main benefits of comparing multiple car insurance quotes. For more info and free online quotes, please visit https://compare-autoinsurance.Org/the-advantages-of-comparing-prices-with-car-insurance-quotes-online/ The modern society has numerous technological advantages. One important advantage is the speed at which information is sent and received. With the help of the internet, the shopping habits of many persons have drastically changed. The car insurance industry hasn't remained untouched by these changes. On the internet, drivers can compare insurance prices and find out which sellers have the best offers. View photos The advantages of comparing online car insurance quotes are the following: Online quotes can be obtained from anywhere and at any time. Unlike physical insurance agencies, websites don't have a specific schedule and they are available at any time. Drivers that have busy working schedules, can compare quotes from anywhere and at any time, even at midnight. Multiple choices. Almost all insurance providers, no matter if they are well-known brands or just local insurers, have an online presence. Online quotes will allow policyholders the chance to discover multiple insurance companies and check their prices. Drivers are no longer required to get quotes from just a few known insurance companies. Also, local and regional insurers can provide lower insurance rates for the same services. Accurate insurance estimates. Online quotes can only be accurate if the customers provide accurate and real info about their car models and driving history. Lying about past driving incidents can make the price estimates to be lower, but when dealing with an insurance company lying to them is useless. Usually, insurance companies will do research about a potential customer before granting him coverage. Online quotes can be sorted easily. Although drivers are recommended to not choose a policy just based on its price, drivers can easily sort quotes by insurance price. Using brokerage websites will allow drivers to get quotes from multiple insurers, thus making the comparison faster and easier. For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.Org/ Compare-autoinsurance.Org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc. "Online quotes can easily help drivers obtain better car insurance deals. All they have to do is to complete an online form with accurate and real info, then compare prices", said Russell Rabichev, Marketing Director of Internet Marketing Company. CONTACT: Company Name: Internet Marketing CompanyPerson for contact Name: Gurgu CPhone Number: (818) 359-3898Email: [email protected]: https://compare-autoinsurance.Org/ SOURCE: Compare-autoinsurance.Org View source version on accesswire.Com:https://www.Accesswire.Com/595055/What-Are-The-Main-Benefits-Of-Comparing-Car-Insurance-Quotes-Online View photos
to request, modification Contact us at Here or [email protected]
 |
 |
 |
